In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity. “This group is just not ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $109.00. The company’s ...
For comparison, Roche's oral GLP-1 achieved 6.1% placebo-adjusted weight at the optimum dose in its phase 1 trial, while Viking's VK2735 – like Zepbound, a dual GLP-1 and GIP agonist – also ...
Pre-market: 9:26:06 am GMT-5 ...
At close: January 28 at 4:00:00 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback